Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 524632 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Shukra Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Shukra Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Shukra Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -6.3% | -1.1% | 3.4% | 3.5% | 3.4% | 2.3% | -0.2% | 0.7% | 4.2% | 18.4% | - |
| Value Creation Index ⓘ | -1.5 | -1.1 | -0.8 | -0.8 | -0.8 | -0.8 | -1.0 | -1.0 | -0.7 | 0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 4.4 | 2.6 | 4.8 | 5.1 | 5.3 | 5.7 | 11.9 | 11.2 | 20.5 | 58.8 | 110 |
| Sales YoY Gr. | - | -41.8% | 87.2% | 6.4% | 3.9% | 6% | 109.4% | -5.5% | 83% | 187.1% | - |
| Adj EPS ⓘ | -0.3 | -0.1 | 0.2 | 0.2 | 0.2 | 0.2 | -0 | 0.1 | 0.3 | 1 | 4.2 |
| YoY Gr. | - | NA | NA | 0% | 5.9% | -16.7% | -106.7% | NA | 400% | 304% | - |
| BVPS (₹) ⓘ | 4.6 | 4.6 | 4.7 | 4.8 | 5 | 5.1 | 5.1 | 5.2 | 5.4 | 16.2 | 49 |
| Adj Net Profit ⓘ | -0.8 | -0.2 | 0.5 | 0.5 | 0.5 | 0.5 | 0 | 0.1 | 0.8 | 4.4 | 19 |
| Cash Flow from Ops. ⓘ | -3.1 | -2 | 2.7 | -0.3 | 0.8 | 0.3 | 1.2 | 0.5 | 8 | 3.2 | - |
| Debt/CF from Ops. ⓘ | -0.1 | -0.6 | 0 | -0.1 | 4.3 | 23.4 | 6.5 | 18.2 | 0.4 | 1.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 33.3% | 61.6% | 70.6% | 187.1% | ||||
| Adj EPS ⓘ | NA | 41.2% | NA | 304% | ||||
| BVPSⓘ | 15% | 26.5% | 46.7% | 197.6% | ||||
| Share Price | 100.7% | 94.6% | 173.6% | 371.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -11.3 | -1.1 | 3.6 | 3.5 | 3.6 | 3 | -0.2 | 0.9 | 4.7 | 21.2 | 13 |
| Op. Profit Mgn % ⓘ | -2.1 | -9.6 | 24.5 | 28.5 | 30.2 | 29.1 | 13 | 12.9 | 14.1 | 9.1 | 16.9 |
| Net Profit Mgn % ⓘ | -17 | -6 | 10.4 | 9.8 | 9.9 | 8.2 | -0.3 | 1.2 | 3.7 | 7.5 | 16.9 |
| Debt to Equity ⓘ | 0 | 0.1 | 0 | 0 | 0.2 | 0.4 | 0.5 | 0.6 | 0.2 | 0.2 | - |
| Working Cap Days ⓘ | 390 | 879 | 392 | 379 | 467 | 526 | 334 | 487 | 277 | 201 | 74 |
| Cash Conv. Cycle ⓘ | 90 | 165 | 75 | 64 | 31 | 40 | 39 | 132 | 54 | -11 | 30 |
Return on Equity has increased versus last 3 years average to 13.00%
Sales growth is growing at healthy rate in last 3 years 70.59%
Sales growth is good in last 4 quarters at 476.97%
Net Profit has been subdued in last 3 years 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 4.2 | - |
| TTM Sales (₹ Cr.) | 110 | - |
| BVPS (₹.) ⓘ | 49 | - |
| Reserves (₹ Cr.) ⓘ | 43 | - |
| P/BV ⓘ | 1.73 | - |
| PE ⓘ | 20.03 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 17.13 / 97.00 |
| All Time Low / High (₹) | 0.02 / 97.00 |
| Market Cap (₹ Cr.) | 371 |
| Equity (₹ Cr.) | 43.8 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 47.2 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 |
| Operating Expenses ⓘ | 5 | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 |
| Manufacturing Costs | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| Material Costs | 3 | 1 | 2 | 1 | 1 | 1 | 3 | 3 | 10 | 45 |
| Employee Cost | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 4 | 5 | 4 |
| Other Costs ⓘ | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| Operating Profit ⓘ | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 |
| Operating Profit Margin (%) | -2.1% | -9.6% | 24.5% | 28.5% | 30.2% | 29.1% | 13.0% | 12.9% | 14.1% | 9.1% |
| Other Income ⓘ | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Exceptional Items ⓘ | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 |
| Tax ⓘ | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 4 |
| PAT Margin (%) | -17.2% | 5.1% | 2.5% | 9.8% | 9.8% | 8.2% | 0.3% | 1.7% | 3.7% | 7.5% |
| Adjusted EPS (₹) | -0.3 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.0 | 0.1 | 0.3 | 2.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 14 | 14 | 14 | 15 | 15 | 15 | 15 | 16 | 16 | 25 |
| Share Capital ⓘ | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 |
| Reserves ⓘ | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 4 |
| Long Term Debt | 0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 4 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Payables | 2 | 1 | 1 | 1 | 2 | 3 | 6 | 5 | 9 | 34 |
| Others Liabilities ⓘ | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 12 |
| Total Liabilities ⓘ | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 |
Fixed Assets | ||||||||||
| Gross Block | 19 | 20 | 20 | 21 | 26 | 29 | 32 | 34 | 35 | 40 |
| Accumulated Depreciation | 10 | 10 | 11 | 11 | 12 | 13 | 14 | 16 | 18 | 19 |
| Net Fixed Assetsⓘ | 10 | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 |
| CWIP ⓘ | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 3 |
| Trade Receivables | 1 | 1 | 1 | 2 | 3 | 5 | 8 | 10 | 7 | 30 |
| Cash Equivalents | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 4 |
| Others Assetsⓘ | 5 | 4 | 3 | 4 | 5 | 5 | 5 | 4 | 4 | 16 |
| Total Assets ⓘ | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -3 | -2 | 3 | 0 | 1 | 0 | 1 | 1 | 8 | 3 |
| PBT ⓘ | -1 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 |
| Adjustment ⓘ | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 2 |
| Changes in Working Capital ⓘ | -3 | -4 | 2 | -1 | -1 | -1 | -1 | -1 | 5 | -3 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | 2 | 1 | 0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 |
| Capex | 2 | 1 | 0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 2 | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | -6 | 1 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 2 | 1 | -1 | 0 | 4 | 2 | 2 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 4 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -11.39 | 0.94 | 0.85 | 3.51 | 3.55 | 3.04 | 0.23 | 1.21 | 4.7 | 21.16 |
| ROCE (%) | -5.78 | 1.83 | 2.4 | 7.41 | 5.94 | 3.62 | 0.77 | 0.54 | 5.79 | 18.85 |
| Asset Turnover Ratio | 0.29 | 0.14 | 0.27 | 0.28 | 0.27 | 0.25 | 0.44 | 0.32 | 0.58 | 1.07 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | 0 | 1 | N/A | N/A | N/A | 8 | 0.75 | Working Capital Days |
| Receivable Days | 73 | 74 | 55 | 121 | 171 | 228 | 177 | 289 | 153 | 117 |
| Inventory Days | 95 | 172 | 67 | 27 | 15 | 11 | 22 | 50 | 50 | 22 |
| Payable Days | 126 | 255 | 97 | 245 | 526 | 872 | 563 | 762 | 246 | 173 |
Shukra Pharmaceuticals is an ambitious organisation with a deep rooted focus on sustainability with its impressive range of solutions. The company is committed to deliver excellence across National & Global markets. It is a public limited organisation with globally acclaimed manufacturing facilities.
The company is strongly committed to its values that guide it - The Shukra Group in serving the needs of its stakeholders including customers, suppliers, employees and other interest groups by large. Shukra stands for uncompromising quality and efficiency to deliver proven solutions delivered by passionate and motivated team of individuals.
The company boasts fully integrated structure for manufacturing general formulations like Tablet, Capsules and small volume parenteral since 2017. Along with internationally accredited facilities it invests in people.
The company has embarked upon its ambitious journey in the field of Pharamaceutical (date of inception) with a fully integrated plant in Rakanpor in Kalol, Gandhinagar - Gujarat. Since then, there was no looking back, within a short span of (years) the company has come a long way in making its mark in the sector.
The company has now developed an internationally accredited Laboratory in Ahmedabad where each product and solutions are developed under stringent quality processes.
Business area of the company
The company is engaged in the business of manufacturing and trading of pharmaceuticals Products, laboratory testing.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
